FarmacoFem by María

FDA has issued 7 warning letters linked to 20+ violative products with concerns about GLP-1 and other products sold to consumers marked for “research purposes” or “not for human consumption”. These products may pose serious health risks. Do not use or purchase unapproved GLP-1 products marketed for research purposes. fda.gov/inspections-co…

This is URGENT. I’m the first Guatemalan woman in the Women@Dior & UNESCO program and I have critical international press commitments this week. Please help me restore access to my network! 🆘🇬🇹🇫🇷

Hey @LinkedInHelp @LinkedIn, My account is locked due to an identity verification loop with @Persona, even though I was verified less than a month ago. System says: "You've already submitted a request. Please try again later."

This is URGENT. I’m the first Guatemalan woman in the Women@Dior & UNESCO program and I have critical international press commitments this week. Please help me restore access to my network! 🆘🇬🇹🇫🇷 My account: majoaguila_27@outlook.es #linkedinhelp

Hey @LinkedInHelp @LinkedIn @dan_shapero, My account is locked due to an identity verification loop with @Persona, even though I was verified less than a month ago. System says: "You've already submitted a request. Please try again later." #LinkedInHelp #LinkedIn

Andrew Huberman: "This is going to be a trillion-dollar drug."

@forallcurious This is a picture of the team btw, Dr. Barbacid was the leader but not the only one to deserve credit.

today, we’re sharing Breyer Capital’s 2026 Healthcare and Life Sciences Predictions. the 2026 forecast calls for the evolution of business models for clinical and bio AI, the maturation of infrastructure for prevention and the biology of aging, and a bioengineering renaissance unlocking in vivo medicine, all while autonomous AI takes shape in both the lab and the clinic. read here:

#PRESS We are announcing a new phase of our partnership with Aspect Biosystems to develop curative medicines for diabetes. Learn more in our press release here: novonordisk.com/content/nncorp…

$NVO announced an update on their ongoing clinical study. $NVO has completed a Phase 3 study titled “Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise.” The study looked at how well CagriSema lowers blood sugar and body weight in adults with type 2 diabetes who are managed only with diet and exercise. The goal is to show that CagriSema can add meaningful glucose control and weight loss on top of lifestyle changes, which is important for long-term diabetes management and could expand Novo Nordisk’s metabolic franchise.

🚨 Novo News Novo's US public affairs chief just walked out the door on the exact day the company rolled out its new Wegovy pill in America. Why? The News Reuters reports that Jennifer Duck, Novo Nordisk's head of US public affairs, has left the company (he Ducked out, if you will :), per an internal memo seen by Reuters. Duck led the US public affairs function for more than 6 years and worked on high-profile US Senate initiatives and Inflation Reduction Act pricing processes. The memo says she chose to pursue opportunities outside the company, and Chris Pernie will run the US public affairs team on an interim basis, effective immediately. Novo confirmed her departure and said her last day was Friday. This lands in the middle of CEO Mike Doustdar's broader shake-up, including large job cuts, and alongside Novo's push to stabilise its US story amid pressure from President Donald Trump on drug pricing and intensifying competition with Eli Lilly $LLY. Novo also recently hired US pharma veteran Greg Miley as global head of corporate affairs, explicitly to help navigate the political and pricing climate. My Take This is not a pipeline headline but rather a power-and-perception headline. Novo's US problem is no longer just "make the next molecule." It's access, pricing, reimbursement, and political theatre, all at once. Public affairs is part of the product in the US. If you are trying to regain share, defend pricing, manage Medicare and self-pay optics, and keep regulators calm, the person running that room matters... A lot. Duck leaving can be read two ways, and markets will pick whichever fits their mood that day. One, normal turnover during a re-org. A new CEO brings a new structure, and people cycle out. Two, a signal that Novo is actively rewiring its US political posture as the Trump pricing pressure rises and the company tries to stop bleeding narrative points to Lilly. The key detail is timing. The company is trying to re-launch momentum in the US, and it is doing it with affordability levers, distribution, and direct-to-consumer moves. That puts comms, government affairs, and stakeholder management on the critical path, not in the back office. So the stock move makes sense too. Shares can pop on "we are finally acting" even while investors quietly note that the fight has shifted from clinical superiority to execution under scrutiny. In GLP-1, Washington is not background noise anymore, it is, in my opinion, part of the competitive arena. Verdict: Neutral Important signal about strategy and internal reshuffling, but not a fundamentals changer by itself.

$NVO They launched oral-Wegovy pretty fast, aiming for early domination with a very low price point and broad availability. If they can reach masses, I don’t think $LLY can catch them easily as oral-Wegovy performs better than orforglipron. Why shouldn’t this work from here?

$NVO -This is how fast sentiment can change. We gonna be rich!

#PRESS The first GLP-1 pill for the treatment of obesity is now broadly available across America. Learn more in the press release here: novonordisk.com/content/nncorp…

Introducing PeptiVerse 🚀, our open-source platform for therapeutic peptide property prediction. We support WT and modified SMILES inputs, and can predict solubility💧, permeability🔬, hemolysis🩸, non-fouling👯, half-life⏱️, tox ☠️, and binding affinity🔗 -- try it out! 🤗: huggingface.co/spaces/Chatter… 📜: biorxiv.org/content/10.648… 🧵👇

Starlink is providing free broadband service to the people of Venezuela through February 3, ensuring continued connectivity.

For all the folks wringing their hands in fake moral outrage over Pres. Trump’s action on Maduro, you have ZERO understanding of the geopolitical significance this action for not just Venezuela but for Western Civilization..let this Venezuelan educate u 👇🏾

🚨 BREAKING: Google Research just dropped the textbook killer. Its called "Learn Your Way" and it uses LearnLM to transform any PDF into 5 personalized learning formats. Students using it scored 78% vs 67% on retention tests. The education revolution is here.